Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on - Molica - 2020 - Hematological Oncology - Wiley Online Library
Frontiers | Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug | OTT
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
Ibrutinib (PCI-32765) | Btk Inhibitor | MedChemExpress
Ongoing or planned phase 3 trials in the first-line setting for CLL | Download Table
Treatment Initiation and Selection in Newly Diagnosed CLL - ppt download
CHRONIC LYMPHOCYTIC LEUKEMIA
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia - ScienceDirect
Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era | American Society of Clinical Oncology Educational Book
1858-Ibrutinib | eviQ
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results | Blood Cancer Journal
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia | Annals of Hematology
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia | NEJM
ALLIANCE A041202 - Study Design | IMBRUVICA® (ibrutinib) HCP
Venetoclax regimen not superior to standard therapy alone for older patients with CLL
COMMISSION DE LA TRANSPARENCE
Ibrutinib and Rituximab (IR) is Superior to Chemo-immunotherapy (CIT) in CLL: Big News, or is it really? And did they get it right? - CLL Society
Ibrutinib in Combination with Rituximab or Lenalidomide/Rituximab for Untreated FL | Research To Practice
Studies on ibrutinib for newly diagnosed chronic lymphocytic leukemia... | Download Scientific Diagram
British Journal of Haematology | Wiley Online Library
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
Ibrutinib's Cardiotoxicity Comes Into Focus | MedPage Today
